Kyowa Hakko Kirin Co., Ltd. (KY4.F)
| Previous close | 15.50 |
| Open | 15.40 |
| Bid | 15.30 x 129600 |
| Ask | 15.90 x 126400 |
| Day's range | 15.40 - 15.40 |
| 52-week range | 14.00 - 20.40 |
| Volume | |
| Avg. volume | 12 |
| Market cap | 8.43B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 23.69 |
| EPS (TTM) | 0.65 |
| Earnings date | N/A |
| Forward dividend & yield | 0.36 (2.36%) |
| Ex-dividend date | 27 Jun 2024 |
| 1y target est | N/A |
Business WireFirst Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
TOKYO, April 15, 2024--On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, "Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)", a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subt
PR NewswireKyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
Kyowa Kirin Co., Ltd. (TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, today announced that pre-clinical data of tivozanib (KHK-4951), an investigational product, assessing the ocular pharmacokinetics of a novel tivozanib eye drop for neovascular age-related macular degeneration (nAMD), will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to b
- PR Newswire
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product in patients with moderate-to-severe atopic dermatitis (msAD), will be presented at the American Academy of Dermatology (AAD) 2024 Annual Meeting to be held in San Diego from March 8-12, 2024.
